期刊文献+

一个纤维蛋白原α链Arg 19 Gly突变导致的遗传性异常纤维蛋白原血症家系 被引量:9

Inherited Dysfibrinogenemia Caused by Arg19Gly in theαChain of Fibrinogen
下载PDF
导出
摘要 目的对一个遗传性异常纤维蛋白原血症家系进行表型和基因型分析。方法采集先证者及其父母外周血进行常规出凝血检查,用Clauss法和免疫比浊法分别检测纤维蛋白原(Fbg)活性和抗原。抽提DNA,PCR扩增纤维蛋白原基因FGA、FGB和FGG所有外显子及其侧翼序列,DNA测序并与基因文库比对确定基因异常。结果先证者活化部分凝血酶原时间(aPTT)、凝血酶原时间(PT)正常,凝血酶时间(TT)为28.10 s,Fbg活性明显下降,抗原在正常范围内,活性显著低于抗原;其父表型检测结果与之相似。基因分析发现,先证者及其父亲Fbg、FGA基因第2外显子均存在A1211G杂合碱基置换,导致Arg19Gly错义突变。结论鉴定该病例为遗传性异常纤维蛋白原血症,Fbgα链Arg19Gly杂合错义突变是致病原因。 Objective To analyze the phenotype and genotype of a family with inherited dysfibrinogenemia. Methods Venous blood samples were collected from the proband and his siblings, and routine coagulation tests were conducted. The activity and antigen of fibrinogen in plasma were measured by functional and immunoturbldlmetry assay, respectively. All the exons and exonintron boundaries of the three fibrinogen genes were analyzed by direct sequencing. Results The proband had normal activated partial thromboplastin time (aFFF) and prothrombin time (PT), but prolonged thrombin time (28.10 s). His plasma fibrinogen antigen was normal, but fibrinogen activity level was reduced (0.7g/L), which was also found in his father. The sequencing results of the proband revealed heterozygous A1211G in the exon 2 of FGA gene originating from his father, which caused Arg19Gly missense mutation. Conclusion Dysfibrinogenemia in the family is caused by Arg19Gly in the α chain of fibrinogen and it is the second report on a Chinese family with inherited dysfibrinogenemia.
出处 《血栓与止血学》 2009年第5期198-202,共5页 Chinese Journal of Thrombosis and Hemostasis
关键词 遗传性异常纤维蛋白原血症 纤维蛋白原 基因突变 Inherited dysfibrinogenemia Fibrinogen Gene mutation
  • 相关文献

参考文献16

  • 1ROBERTS HR, STINCHCOMBE TE, GABRIEL DA. The Dysfibrinogenaemias [ J ]. Br J Haematol,2001,114 :249- 257.
  • 2方怡,王学锋,傅启华,武文漫,丁秋兰,戴菁,周荣富,王文斌,谢爽,王鸿利.一个纤维蛋白原γ链Arg275His突变导致的遗传性异常纤维蛋白原血症家系[J].中华医学遗传学杂志,2005,22(2):201-203. 被引量:27
  • 3NEERMAN-ARBEZ M ,DE MOERLOOSE P,BRIDEL C ,et al. Mutations in the fibrinogen Aa gene account for the majority of cases of congenital afibrinogenemia [ J ]. Blood,2000,96 : 149-152.
  • 4BLOMB? CK B, HESSEL B,FIELDS R, et al. Fibrinogen Aarhus - a new case of dysfibrinogenemia [J]. Thrombosis Research, 1986.42:21-37.
  • 5YAMAGUCHI S, SUGO T, HASHIMOTO Y, et al. Fibrinogen Kumamoto with an Act Arg- 19 to Gly substitution has reduced affinity for thrombin possible relevance to thrombosis [ J ]. Jap J Thromb Haemost, 1997, 8: 382-392.
  • 6DEMPFLE C-EH, Henschen A. Fibrinogen Mannheim I-Identification of an Aα19 Arg-→Gly substitution in dysfibrinogenaemia associated with bleeding tendency [ J ]. Elsevier Science Publishers BV, Amsterdam, 1990, pp 159-166.
  • 7HITOSHI TANAKA, FUMIHIRO ISHIDA, KIYOSHI KITANO,et al. Fibrinogen Matsumoto V: a Variant with Aα 19 Arg→Gly( AGG→GGG). Thromb Haemost, 2001, 85:108-113.
  • 8BOLLIGER-STUCKI B, BUCCIARELLI P, LMMLE B, et al. Fi- brinogen Milano ⅩⅢ (Aα 19 Arg→Gly) : a dysfunctional variant with an amino acid substitution in the N-terminal polymerization site [J]. Thromb Res ,1999, 96: 399-405.
  • 9BRENNAN SO, RIDGWAY H, STORMORKEN H, et al. Characterisation of fibrinogen Oslo Ⅳ by electrospray mass spectrometry [J]. Thromb Haemost, 1997, 77: 1040-1041.
  • 10KUDRYK B, BLOMB? CK B, BLOMB? CK M. Fibrinogen Detroit - an abnormal fibrinogen with non-functional NH2- terminal polymerization domain [ J ]. Thromb Res, 1976, 9 : 25- 36.

二级参考文献11

  • 1Yamazumi K, Terukina S, Onohara S, et al. Normal plasmic cleavage of the gamma-chain variant of "fibrinogen Saga" with an Arg-275 to His substitution. Thromb Haemost,1988, 60:476-480.
  • 2Yoshida N, Imaoka S, Hirata H, et al. Heterozygous abnormal fibrinogen Osaka Ⅲ with the replacement of gamma arginine-275 by histidine has an apparently higher molecular weight gamma-chain variant. Thromb Haemost,1992, 68:534-538.
  • 3Siebenlist KR, Mosesson MW, Di Orio JP, et al. The polymerization of fibrin prepared from fibrinogen Haifa (gamma 275Arg→His). Thromb Haemost,1989, 62:875-879.
  • 4Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature, 1997, 389:455-462.
  • 5Siebenlist KR, Mosesson MW, Meh DA, et al. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis,2000, 11:293-304.
  • 6Neerman-Arbez M, de Moerloose P, Bridel C, et al. Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia.Blood,2000,96:149-152.
  • 7Roberts HR, Stinchcombe TE, Gabriel DA. The Dysfibrinogenaemias. Br J Haematol, 2001,114:249-257.
  • 8Reber P, Furlan M, Henschen A, et al. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg→His): fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost,1986, 56:401-406.
  • 9Borrell M, Gari M, Coll I, et al. Abnormal polymerization and normal binding of plasminogen and t-PA in three new dysfibrinogenaemias: Barcelona III and IV (gamma Arg 275→His) and Villajoyosa (gamma Arg 275→Cys). Blood Coagul Fibrinolysis,1995, 6:198-206.
  • 10Steinmann C, Jungo M, Beck EA, et al. Fibrinogen Claro-another dysfunctional fibrinogen variant with gamma 275 arginine→histidine substitution. Thromb Res,1996, 81:145-150.

共引文献26

同被引文献88

引证文献9

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部